roton magnetic resonance spectroscopy (1H-MRS) uses the same hardware as magnetic resonance imaging (MRI) to measure various metabolites in the brain. With suppression of the large proton signal from water molecules, the intensity of the relaxation signal from protons attached to other brain metabolites of interest can be quantified in the time domain, as free induction decays (FID). These FIDs are usually Fourier transformed to the frequency domain and depicted as spectra. The area under the curve at a particular frequency (usually in parts per million [ppm] to standardize across magnetic field strengths), can then be quantified and usually referenced to an internal standard (like water spectra or another neurometabolite, eg, total creatine). With traditional clinical 1.5-Tesla (T) scanners the main metabolites of interest include N-acetylaspartate compounds (NAA plus N-acetylaspartate-glutamate, NAAG), choline (Cho) and creatine (Cre). At higher field strengths (3, 4, and 7 T), the more complex overlapping, multiplets corresponding to glutamate (Glu), glutamine (Gln) and myoinositol (Ins), can also be measured. γ−Aminobutyric acid (GABA) as well as gluthatione (GSH) can be quantified at the higher filed P h a r m a c o l o g y 
strengths with special editing techniques. Most studies have used single voxel acquisition (anywhere between 1 to 40 cc per voxel). This is practical for populations where support for regional pathology is strong. Chemical shift imaging (CSI), simultaneously acquires many voxels (20 to 100, usually 1 to 2 cc each) across a slab of tissue, providing better spatial coverage. However, spectral resolution can be compromised due to magnetic field inhomogeneity. Interpretation of the meaning of differences in levels measured depends on what is known about the physiology of the various neurometabolites. NAA is the second most concentrated aminoacid in the brain (after glutamate). NAA is synthesized in neuronal mitochondria and is located almost exclusively in neurons and their processes. Hence, in neurodegenerative and vascular disease NAA is reduced and it is absent from brain tumor tissue. Consequently, NAA is viewed as a marker of neuronal viability. However, NAA clearly is not a neurotransmitter or neuromodulator, and its function remains unclear. It has been hypothesized to serve as an osmolyte and an acetate donor involved in myelinization. Choline compounds are trimethylamines but are chemically heterogeneous and have a twofold greater concentration in glial compared with neuronal cells. Consistently, the choline signal tends to be increased in neurodegenerative disorders with gliosis and/or increased membrane turnover. Myoinositol is the most abundant biologically active stereoisomer of inositol in the brain. Myoinositol is a precursor in the phosphatidylinositol second messenger system, and is also a glial marker. In dementia, elevated Ins, in conjunction with reduced NAA, has been consistently found. Glutamate is an aminoacid highly concentrated in all cells and involved in multiple metabolic functions. It is the principal excitatory neurotransmitter in the central nervous system (CNS). However, only a minimal proportion of 1 H-MRS-measured glutamate signal comes from the synapses. Conversely, glutamine is mainly synthesized in the glia from synaptic glutamate and has been used as an index of glutamatergic neurotransmission. GABA is the principal inhibitory neurotransmitter in the CNS. Although technically challenging, its 1 H-MRS measurement can be more easily interpreted than the levels or glutamate or even glutamine. Finally, creatine and phosphocreatine are easily measured and are involved in energy metabolism. Although often used as a reference for other metabolites, interpretation of the meaning of creatine group differences is poorly understood.
Schizophrenia

Disease-related findings
Over the last three decades there have been many 1 H-MRS studies comparing schizophrenic (Sz) and healthy control groups, and these have been summarized in three meta-analyses. Steen 3 reported increased Gln and Gln/Glu ratio in medial frontal cortex, more apparent earlier than later in the illness. In the last 4 years a few studies have examined GABA in Sz and the results have been inconsistent: two studies found reductions, 4,5 two elevations, 6, 7 and one no differences. 8 Finally, one study detected gluthathione reductions in frontal cortex as well as in cerebrospinal fluid of drug-free Sz. 9 This literature confirms that in schizophrenia (mostly chronically treated patients) there are reductions in NAA in frontal and basal ganglia regions, consistent with neuronal dysfunction (postmortem literature has consistently failed to find neuronal loss). A more limited literature supports elevations of Gln in medial frontal regions, suggestive of increased glutamatergic neurotransmission.
Treatment-related studies
Treatment studies using 1H-MRS not surprisingly lag in number compared with cross-sectional investigations. Most of them have been naturalistic observations before and after treatment with antipsychotic agents. Theberge et al 10 examined antipsychotic-naïve Sz subjects at baseline, 10, and 30 months following antipsychotic treatment. Baseline thalamic Gln elevations were decreased at 30 months, and correlated with widespread temporal and parietal gray matter reductions. This was interpreted as evidence of glutamate-related disease progression, not as a medication effect (at 10 months, Gln did not change). Although a few studies have reported increases in NAA with treatment, the majority have failed to do so. Bertolino et al, 11 in a retrospective study, reported higher NAA/Cre in the dorsolateral prefrontal cortex in patients while treated with antipsychotic medication compared with when they were medication-free. Fannon et al 12 reported reduced medial temporal NAA/Cre at baseline, which was no longer statistically different from healthy subjects after 3 months of atypical antipsychotic treatment. However, Choe et al 13 found low frontal NAA/Cre at baseline with no changes after treatment with typical and atypical agents (follow-up 1-6 months). We found frontal and striatal NAA reductions in minimally treated patients that did not change following 9-month randomized treatment with quetiapine or haloperidol. 14 Szulc et al 15 reported no NAA changes following treatment with various antipsychotics. Finally, Theberge et al 10 found no NAA changes following a 30-month treatment. These clinical studies are generally consistent with largely negative findings in the animal 1 H-MRS literature examining antipsychotic exposure in rats. Lindquist et al 16 found no reductions of frontal NAA after 1 week of haloperidol but a reduction with olanzapine. We found no changes in NAA after 6 weeks of clozapine or haloperidol. 17 Additionally, 6 months exposure to haloperidol produced no changes in NAA, Glu, Gln, or GABA. 18 However, Harte et al 19 did find increased NAA in the rat striatum with long-term haloperidol exposure, consistent with dendritic sprouting. Antipsychotic drugs are known to induce structural volume increases in the human striatum 20 and cortical volume reductions, 21 but no neuronal loss. Hence, the ability to detect changes in neuronal tissue concentration would depend on the spatial resolution of the 1H-MRS technique (currently limited to 1 cc, clearly suboptimal for the 2-to 3-mm thick human cortex) as well as the timing of acquisition. A recent longitudinal study of antipsychotic-naïve schizophrenia examined Glu and NAA in the caudate before and 4 weeks following treatment with risperidone. 22 Baseline Glu elevations normalized with treatment but there were no changes in NAA. However, the Glu normalization did not correlate with symptom improvement. These results are consistent with a dopamine D2 modulation of striatal hypeglutamatergia. Consistently, Goto et al 23 reported similar Glx prefrontal reductions following 6 months of antipsychotic treatment.
Experimental agent studies
Few studies have used 1 H-MRS to examine neurochemical effects of non-dopamine D2 blockers for potential applications in schizophrenia. Jarkog et al 24 recently examined the effect of adjunct davunetide (a neurotrophic peptide) for 12 weeks in schizophrenia. Higher-dose davunetide (30 mg/day) resulted in marginal prefrontal NAA and Cho increases, suggesting a neuroprotective effect. However, there were no correlations with symptoms or cognitive measures. Glycine has been examined for the treatment of negative symptoms, and an 1 H-MRS sequence is sensitive enough to detect brain elevations in the context of oral administration in healthy volunteers. 25 Future studies may examine the glycine spectra in clinically treated populations. Finally, in a knockout mouse model with reduced glutathione, N-acetyl cysteine administration during gestation was found to revert abnormally elevated prepuberal brain Gln and Gln/Glu. 26 This is somewhat consistent with a study documenting effects of N-acetyl cysteine (NAC) on negative symptoms. 27 However, there have been no reports examining the effects of NAC on 1 H-MRS measures in schizophrenia.
P h a r m a c o l o g y
Bipolar disorder
Disease-related findings The Kraguljac et al 2 meta-analysis reported NAA reductions only in basal ganglia and elevations in dorso lateral prefrontal cortex (however, heterogeneity of studies was high for the latter). There were no differences in Cre or Cho. In another meta-analysis 28 Glx was found to be elevated, mainly in the frontal region, regardless of medication or clinical state. 29 One study reported reduced occipital GABA. 30 These results suggest increased glutamatergic indices in bipolar disorder, without the more widespread neuronal dysfunction (reduced NAA) found in schizophrenia.
Treatment-related studies
Some studies have used 1 H-MRS in bipolar mania to evaluate correlates of treatment with lithium, other mood stabilizers, and antipsychotic agents.
Lithium
Cross-sectional studies suggested that lithium therapy increases NAA 31, 32 in bipolar patients. However, longitudinal human studies 33, 34 as well as a rodent study 35 failed to detect NAA changes. Conversely, reductions in Glx have been reported in longitudinal human 33 and rat 35 studies with lithium, consistent with an improvement of Glx in bipolar disorder. However, documentation of a relationship between Glx reductions and symptom improvement is lacking. Additionally, lithium induced myo-inositol reductions which did not relate to changes in mood, 36 but another longitudinal study found increases in this metabolite. 33 In general, no clear pattern of lithium related 1 H-MRS changes has been documented in clinical populations. However, spectroscopic measurement of brain lithium in treated bipolar subjects does correlate with serum lithium levels. 37 This approach may result in a clinical application for lithium MRS in the future.
Other agents
Strawn et al 38 studied adolescents in a manic episode before open-label treatment with divalproex and 1 and 4 weeks later. Remitters had lower Glx in the left ventro lateral prefrontal cortex compared with nonremitters. However, in adult bipolar patients treated with valproic acid, Glx failed to predict response. 33 In rats, sodium valproate did induce reductions in glutamate. 35 
Depression
Disease-related findings
Two meta-analyses have examined 1H-MRS neurometabolite findings in major depressive disorder. Yildiz-Yesiloglu and Ankerst 39 reported an increase in Cho/Cre ratio in basal ganglia in major depression with no changes in NAA. This was interpreted as increased membrane turnover without evidence of neuronal damage. More recently, Glx was found reduced in the anterior cingulate cortex during a depressive episode. 40 This suggests that contrary to bipolar mania, glutamatergic metabolism is reduced in a state-dependent relationship in depression. Finally, reduced occipital GABA has been found in MDD.
41,42
Treatment-related studies
Since Cho levels tend to be increased in MDD, some studies have examined their relationship to treatment. Charles et al 43 reported Cho/Cre reductions with nefazodone treatment. However, Cho increases have been reported in other drug 44 and transcranial magnetic stimulation (TMS) 45 studies in treatment responders. Baseline reductions of Glx would be expected to increase with therapy. Indeed, electroconvulsive therapy (ECT) normalized reduced prefrontal Glx 46 and successful TMS increased Glu44 in depression. Regarding GABA, baseline occipital reductions increased with serotonin reuptake inhibitors. 41 Similarly, ECT increased GABA 42 but cognitive behavioral therapy (CBT), failed to do so. 47 Some studies have examined a neurotrophic effect of various treatments by examining NAA. The results for ECT have been mixed in terms of NAA changes. 48, 49 However, there is a modest but consistent literature suggesting increases in NAA with antidepressant medication. [50] [51] [52] Finally, new strategies for depression with NMDA blockers have been studied recently and examinations of glutamate metabolism undertaken. Salvatore et al 53 found that the pretreatment prefrontal Glx/Glu ratio was negatively correlated with improvement in 
Summary of findings
1 H-MRS has been widely used to study major psychiatric illness, and several findings have been consistently reported. In schizophrenia, prefrontal NAA is reduced and glutamine increased, suggestive of glutamate-related excitotoxicity. In bipolar disorder, there is increased prefrontal glutamatergic metabolism (elevated Glx) perhaps as a trait measure. In major depression, basal ganglia choline is increased, while prefrontal Glx and occipital GABA are reduced and these may represent state abnormalities. Presently, none of these effects are sufficiently sensitive or specific to have any diagnostic implication.
The literature regarding applicability of 1 H-MRS to evaluate effects of treatment is, not surprisingly, more limited. In schizophrenia, NAA reductions are not caused, but also not restored, by antipsychotic agents. However, there is evidence that antipsychotics may reduce elevated glutamatergic indices, especially in the striatum, their primary site of action. In bipolar disorder, the 1 H-MRS correlates of response to lithium and other mood stabilizers have not been elucidated. However, lithium quantification in brain is possible and may have future clinical applications. Regarding depression, it is encouraging that restoration of reduced glutamate and GABA have been documented with ECT, TMS, and antidepressant medication. Additionally, a small but reliable increase of NAA with medication is consistent with the neurotrophic effects of antidepressant drugs. However, the correlations with symptom improvement for these 1 H-MRS /treatment relationships have been modest at best and no clinical applications are available. Table I summarizes the strengths and weaknesses of MRS.
Future directions
In terms of technique development there is a need for sequences with broader spatial coverage so that true imaging of multiple metabolites is possible, with enough spatial resolution to allow full integration with other modalities. This would allow, for example, to test whether NAA reductions in white matter in schizophrenia, correspond or not to the well-described reductions in fractional anisotropy (FA), acquired with DTI. Additionally, techniques that reliably block lipid signal contamination, will permit more specific examination of peripheral cortical regions. Improved hardware and shimming techniques may allow measurements in deeper structures, 
